Allergen immunotherapy -: a position paper of the German Society for Allergology and Clinical Immunology

被引:0
|
作者
Kleine-Tebbe, J
Fuchs, T
Klimek, L
Kühr, J
Lepp, U
Niggemann, B
Rakoski, J
Renz, H
Saloga, J
Simon, J
机构
关键词
allergen immunotherapy; hyposensitization; position paper; allergy treatment;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Mechanisms of allergen immunotherapy (AIT) are complex, inducing numerous immunological effects. Successfull AIT is most likely based on a functional switch of and tolerance induction in specific T cells downregulating allergic hypersensitivity and inflammation. Subcutaneous AIT for allergic rhinoconjunctivitis and allergic asthma has been successfully assessed in controlled studies with several clinically important allergens (i.e. birch-, grass- and mugwortpollen, dust mites, animal dander) and has shown convincing clinical efficacy. Considered as the only causal treatment besides allergen avoidance at present, AIT can alter the natural course of allergic diseases. Hymenoptera venom hypersensitivity (to bee- and wasp venom) treated with AIT gives the best results compared to AIT with other allergens. AIT is indicated in patients with IgE-mediated sensitizations and corresponding clinical to allergens, which do not or hardly permit allergen avoidance and which are available as suitable extracts. Decisions about indication and allergen selection should only be made by a physician with certified training or qualified knowledge and skills in allergology. AIT is administered by physicians experienced in this therapy. After addressing tolerability and present status of health, the recommended or individually adjusted dose is injected and precisely documented, followed by a mandatory waiting period of 30 minutes. Indication for and application of AIT in children are quite similar compared to the treatment of adults. Children tolerate AIT very well and benefit especially from its immunomodulatory effects. Risk factors for and results of unwanted systemic effects can effectively be minimized by training of the staff members involved, adhering to safety standards and immediate emergency treatment. Modified allergens, recombinant proteins and immunomodulatory adjuvants created by basic research are promises for an improved efficacy of AIT with reduced unwanted effects in the future.
引用
收藏
页码:535 / 544
页数:10
相关论文
共 50 条
  • [12] Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper
    Eva Untersmayr
    Elisabeth Förster-Waldl
    Michael Bonelli
    Kaan Boztug
    Patrick M. Brunner
    Thomas Eiwegger
    Kathrin Eller
    Lisa Göschl
    Katharina Grabmeier-Pfistershammer
    Wolfram Hötzenecker
    Galateja Jordakieva
    Alexander R. Moschen
    Birgit Pfaller
    Winfried Pickl
    Walter Reinisch
    Ursula Wiedermann
    Ludger Klimek
    Karl-Christian Bergmann
    Randolf Brehler
    Wolfgang Pfützner
    Natalija Novak
    Hans Merk
    Uta Rabe
    Wolfgang Schlenter
    Johannes Ring
    Wolfgang Wehrmann
    Norbert Mülleneisen
    Holger Wrede
    Thomas Fuchs
    Erika Jensen-Jarolim
    Allergo Journal International, 2021, 30 : 155 - 168
  • [13] Immunologically relevant Aspects of the New COVID-19 Vaccines A Position Paper of the Austrian Society for Allergology and Immunology (OEGAI) and the German Society for Applied Allergology (AeDA)
    Untersmayr, Eva
    Foerster-Waldl, Elisabeth
    Bonelli, Michael
    Boztug, Kaan
    Brunner, Patrick M.
    Eiwegger, Thomas
    Eller, Kathrin
    Goeschl, Lisa
    Grabmeier-Pfistershammer, Katharina
    Hoetzenecker, Wolfram
    Jordakieva, Galateja
    Moschen, Alexander R.
    Pfaller, Birgit
    Pickl, Winfried
    Reinisch, Walter
    Wiedermann, Ursula
    Klimek, Ludger
    Bergmann, Karl-Christian
    Brehler, Randolf
    Novak, Natalija
    Merk, Hans
    Rabe, Uta
    Schlenter, Wolfgang
    Ring, Johannes
    Wehrmann, Wolfgang
    Muelleneisen, Norbert
    Wrede, Holger
    Fuchs, Thomas
    Jensen-Jarolim, Erika
    ALLERGO JOURNAL, 2021, 30 (05) : 34 - 47
  • [14] Non-Celiac Gluten Sensitivity: Unclear Etiology and lack of Diagnostic Criteria Position Paper of the German Society of Allergology and clinical Immunology is published
    Schaefer, Christiane
    ERNAHRUNGS UMSCHAU, 2018, 65 (09): : M483 - M483
  • [15] Mastocytosis Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG)
    Hartmann, Karin
    Biedermann, Tilo
    Brockow, Knut
    Grabbe, Juergen
    Horny, Hans-Peter
    Lippert, Undine
    Maurer, Marcus
    Raithel, Martin
    Rietschel, Ernst
    Rueff, Franziska
    Sotlar, Karl
    ALLERGO JOURNAL, 2009, 18 (03) : 196 - 207
  • [16] Clinical contraindications to allergen immunotherapy: an EAACI position paper
    Pitsios, C.
    Demoly, P.
    Bilo, M. B.
    van Wijk, R. Gerth
    Pfaar, O.
    Sturm, G. J.
    Rodriguez del Rio, P.
    Tsoumani, M.
    Gawlik, R.
    Paraskevopoulos, G.
    Rueff, F.
    Valovirta, E.
    Papadopoulos, N. G.
    Calderon, M. A.
    ALLERGY, 2015, 70 (08) : 897 - 909
  • [17] The management of anaphylaxis in childhood:: position paper of the European academy of allergology and clinical immunology
    Muraro, A.
    Roberts, G.
    Clark, A.
    Eigenmann, P. A.
    Halken, S.
    Lack, G.
    Moneret-Vautrin, A.
    Niggemann, B.
    Rance, F.
    ALLERGY, 2007, 62 (08) : 857 - 871
  • [18] COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)
    Pfaar, O.
    Klimek, L.
    Hamelmann, E.
    Kleine-Tebbe, J.
    Taube, C.
    Wagenmann, M.
    Werfel, T.
    Brehler, R.
    Novak, N.
    Muelleneisen, N.
    Becker, S.
    Worm, M.
    ALLERGOLOGIE, 2021, 44 (04) : 261 - 269
  • [19] German guideline for the management of adverse reactions to ingested histamineGuideline of the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SGAI)
    Imke Reese
    Barbara Ballmer-Weber
    Kirsten Beyer
    Thomas Fuchs
    Jörg Kleine-Tebbe
    Ludger Klimek
    Ute Lepp
    Bodo Niggemann
    Joachim Saloga
    Christiane Schäfer
    Thomas Werfel
    Torsten Zuberbier
    Margitta Worm
    Allergo Journal International, 2017, 26 (2) : 72 - 79
  • [20] COVID-19 Vaccination of Patients with Allergies and Type-2 inflammatory Diseases with concurrent Antibody Therapy (Biologicals) A Position Paper of the German Society of Allergology and clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)
    Pfaar, Oliver
    Klimek, Ludger
    Hamelmann, Eckard
    Kleine-Tebbe, Joerg
    Taube, Christian
    Wagenmann, Martin
    Werfel, Thomas
    Brehler, Randolf
    Novak, Natalija
    Muelleneisen, Norbert
    Becker, Sven
    Worm, Margitta
    ALLERGO JOURNAL, 2021, 30 (05) : 24 - 30